CAD-risk: Risk Stratification for Coronary Artery Disease With Type 2 Diabetic Patients

Sponsor
Acarix (Industry)
Overall Status
Completed
CT.gov ID
NCT02494557
Collaborator
Steno Diabetes Center Copenhagen (Other), Rigshospitalet, Denmark (Other)
108
1
5.9
18.2

Study Details

Study Description

Brief Summary

Diabetic type 2 patients (DB2) has a higher prevalence of coronary artery disease (CAD) than non-diabetic persons. Presence of CAD results in murmurs arising from the filling of the arteries and can be detected by the CADScor System and can together with biological patient profile indicate the risk of presence of CAD in the patient. In the pilot study 100 asymptomatic DB2-patients examined with CADScor System and biomarkers will be compared with computed tomography (CT) cardiography and single-photon emission computed tomography (SPECT) for assessing if combination of patient profile (gender, age etc) combined with above measures may give rise to new improved risk scoring method for he DB2-patient.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The study is intended as a pilot observational study for evaluation of a new risk scoring method, CADScor System, is relevant for assessment of CAD in the DB2-patient.

    The primary end point will be to document that the hypothesis of combining the CADScor System measure with other patient profile data will increase the accuracy of the method for determination of risk of presence of CAD.

    The secondary endpoint will be to show that a receiver operating characteristic curve (ROC) of > 80% for correct determination of presence of CAD will be achieved.

    The further objective of the study will be to confirm the relevance of performing a large scale study with equivalent objectives.

    As controls in the study will be applied CT angiography, CT-calcium and resting and drug induced CT-scintigraphy.

    It is assumed that 15-20 of enrolled patients in the study will suffer from CAD.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    108 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Risk Stratification for Coronary Artery Disease With Type 2 Diabetic Patients
    Study Start Date :
    Sep 1, 2014
    Actual Primary Completion Date :
    Mar 1, 2015
    Actual Study Completion Date :
    Mar 1, 2015

    Outcome Measures

    Primary Outcome Measures

    1. Acoustic Cad-score [1 year]

      Comparison of an non-invasive acoustic Cad-score as risk prediction for presence of coronary artery disease with control studies of CT-angiography and resting and drug induced CT scintigraphy

    Secondary Outcome Measures

    1. The degree of presence of coronary artery disease (CAD) in Diabetic type 2 patients (DB2) patients [1 year]

      Resting and drug induced perfusion test will be compared to CT Angiography for determining the degree of presence of CAD when including patient parameters characterizing the status and severity of the DB2.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients suffering from diabetes type 2

    • Both sexes

    • Patients between 40 and 80 years

    • Patients without chest pain at rest and labor

    • Patients having a normal electrocardiogram (ECG, i.e. without Q-peaks/ T-peak abnormalities in sinus rhythm)

    • Patients having intact skin over sternum

    Exclusion Criteria:
    • Patients suffering from a heart disease

    • Patients already having received heart surgery

    • Patients with pacemaker or other implanted electronic device

    • Patients suffering from allergy against iodine and iodine containing substances

    • Patients with estimated GFR below 50 ml/min/1.73 sqm m

    • Patients suffering from adenosine intolerance or known allergic asthma

    • Patients not being capable of understanding the patient information of the study

    • Patients who are pregnant

    • Patients suffering from allergy to adhesives

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Steno Diabetes Center Gentofte Denmark 2840

    Sponsors and Collaborators

    • Acarix
    • Steno Diabetes Center Copenhagen
    • Rigshospitalet, Denmark

    Investigators

    • Principal Investigator: Peter Rossing, Professor, Steno Diabetes Center, Niels Steensensvej 4, 2840 Gentofte, Denmark

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Acarix
    ClinicalTrials.gov Identifier:
    NCT02494557
    Other Study ID Numbers:
    • CAD-risk/2014
    First Posted:
    Jul 10, 2015
    Last Update Posted:
    May 23, 2017
    Last Verified:
    May 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 23, 2017